Search details
1.
Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences.
Nature
; 566(7742): E1, 2019 02.
Article
in English
| MEDLINE | ID: mdl-30659290
2.
Landscape of somatic mutations in 560 breast cancer whole-genome sequences.
Nature
; 534(7605): 47-54, 2016 06 02.
Article
in English
| MEDLINE | ID: mdl-27135926
3.
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.
Lancet
; 393(10191): 2591-2598, 2019 06 29.
Article
in English
| MEDLINE | ID: mdl-31178155
4.
Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes.
Breast Cancer Res
; 19(1): 98, 2017 Aug 22.
Article
in English
| MEDLINE | ID: mdl-28830573
5.
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
Lancet Oncol
; 14(8): 741-8, 2013 Jul.
Article
in English
| MEDLINE | ID: mdl-23764181
6.
A phase III randomized trial of weight loss to reduce cancer-related fatigue among overweight and obese breast cancer patients: MEDEA Study design.
Trials
; 23(1): 193, 2022 Mar 04.
Article
in English
| MEDLINE | ID: mdl-35246219
7.
Fluctuation of the left ventricular ejection fraction in patients with HER2-positive early breast cancer treated by 12 months of adjuvant trastuzumab.
Breast
; 41: 1-7, 2018 Oct.
Article
in English
| MEDLINE | ID: mdl-29913374
8.
French Medico-Administrative Data to Identify the Care Pathways of Women With Breast Cancer.
Clin Breast Cancer
; 17(4): e191-e197, 2017 07.
Article
in English
| MEDLINE | ID: mdl-28237608
9.
Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohort.
Eur J Cancer
; 81: 151-160, 2017 08.
Article
in English
| MEDLINE | ID: mdl-28624696
10.
Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort.
NPJ Breast Cancer
; 3: 4, 2017.
Article
in English
| MEDLINE | ID: mdl-28649644
11.
A phenotypic and mechanistic perspective on heterogeneity of HER2-positive breast cancers.
Mol Cell Oncol
; 3(6): e1232186, 2016.
Article
in English
| MEDLINE | ID: mdl-28090578
12.
GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patients.
Oncotarget
; 7(47): 77358-77364, 2016 Nov 22.
Article
in English
| MEDLINE | ID: mdl-27764800
13.
A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers.
Nat Commun
; 7: 12222, 2016 07 13.
Article
in English
| MEDLINE | ID: mdl-27406316
14.
Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study.
Eur J Cancer
; 51(13): 1660-6, 2015 Sep.
Article
in English
| MEDLINE | ID: mdl-26163096
15.
Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative.
Eur J Cancer
; 51(3): 271-81, 2015 Feb.
Article
in English
| MEDLINE | ID: mdl-25542058
16.
[How to improve patients and investigators' information on clinical trials: the example of French registry for clinical trials in oncology]. / Comment améliorer l'information des patients et des professionnels sur la recherche clinique : le registre français des essais cliniques en cancérologie.
Bull Cancer
; 95(12): 1227-32, 2008 Dec.
Article
in French
| MEDLINE | ID: mdl-19091658
Results
1 -
16
de 16
1
Next >
>>